Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29541238 | 0.80 | ALDH1A1 (0.48) | MAP4K4TSHRKDM4EALDH1A1GAA | |
| SCHEMBL22234100 | 0.78 | CTSB (0.51) | TNKSTSHRKDM4EALDH1A1MEN1 | |
| SCHEMBL30153654 | 0.78 | MMP3 (0.46) | MAP4K4ALDH1A1CA1CA2MMP3 | |
| SCHEMBL30494512 | 0.78 | MMP3 (0.46) | MAP4K4ALDH1A1CA1CA2MMP3 | |
| SCHEMBL4933933 | 0.77 | CA1 (0.47) | TNKSTSHRCA1CA2HRH4 | |
| SCHEMBL18322222 | 0.76 | TSHR (0.52) | TNKSTSHRALDH1A1CA1CA2 | |
| SCHEMBL30451858 | 0.76 | TSHR (0.52) | TNKSTSHRALDH1A1CA1CA2 | |
| SCHEMBL1705257 | 0.74 | ALDH1A1 (0.58) | TSHRKDM4EALDH1A1GAACA1 | |
| SCHEMBL13192001 | 0.74 | TSHR (0.46) | TNKSTSHRCA1CA2MAOB | |
| SCHEMBL29904188 | 0.74 | MAP4K4 (0.44) | MAP4K4CA1CA2HRH4MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-10-22 | — | — | US | disclosed |
| US-20220112160-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-04-14 | — | — | US | disclosed |
| WO-2020150446-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150446-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112160-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, HMOX1 | TNKS 2978/4885MAP4K4 258/4885TSHR 4687/4885 |
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | TNKS 2978/4885MAP4K4 258/4885TSHR 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.